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SUMMARY
The aim of the study was to investigate the potential relationship
between left ventricularhypertrophy (LVH) and fraction with serum leptin in
end-stage renal failure patients undergoing regular hemodialysis treatment. A
cross-sectional study included 41 patients (15women, 26men)with an end-stage
renal disease (ESRD), undergoing maintenance hemodialysis (HD) treatment
with acetate basis dialysate and polysulfone membranes. Serum leptin and
predialysis creatinine and post- and predialysis BUN, calcium (Ca),
phosphorus(P), serum albumin (Alb) and serum ferritin were in the patients
categorized into no LVH, mild, moderate and severe LVH, according to the
performed echocardiographies. The mean patients' age was 46 (±17.6) years.
The average hemodialysis duration was 29.5 (±34) months (median: 18
months). The mean serum leptin was 9.5±13.8 ng/ml (median: 4.7 ng/ml). In
this study, no significant association between stages of LVH with serum leptin
was recorded. Also, a significant positive correlation between LV ejection
fraction and logarithm of serum leptin (r=0.32, p=0.048) (adjusted to age,
duration and doses of dialysis, BMI, DM, serum ferritin, calcium, phosphorus,
and serum Alb) was observed. Leptin might not be an aggravator for the
appearance of LV hypertrophy. This feature of leptin in maintenance
hemodialysis patients, which is in contrast to general population, especially in
obese patients with normal renal function, could be explained through its
reverse epidemiological role in hemodialysis patients. Our results emphasize the
importance of leptin in hemodialysis and clinical impact of these findings on
further investigation.
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INTRODUCTION
Cardiovascular disease is the principal cause
of morbidity and mortality in dialysis patients (1, 2).
The principal alterations responsible are left
ventricular hypertrophy and arterial disease (2). Left
ventricular hypertrophy (LVH) is the consequence of
combined effects of chronic hemodynamic overload
and non-hemodynamic biochemical and
neurohumoral factors characteristic of uremia. LVH
is an independent risk factor (2-4). In recent years,
much progress has been made in understanding the
pathogenesis of cardiovascular disease in the uremic
population (4). Dialysis patients are subject to
atherosclerosis and consequent ischemic heart
disease, but myocardial dysfunction and overt heart
failure also are highly prevalent. In hemodialysis
patients, eighty-four percent of patients have left
ventricular hypertrophy, left ventricular (LV)
dilatation, or low fractional shortening at the
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initation of ESRD therapy. Furthermore, LVH has
-
been found in 38% of patients with chronic renal
failure (CRF) prior to the requirement for dialysis
(1,2). It is clear that the presence of LVH or LV
dilatation (or both) is a poor prognostic factor (2-4).
Many conventional cardiovascular risk factors in the
general population are not so predictive in the end-
stage renal disease (ESRD). In the general
population, plasma leptin concentrations have been
found associated with LVmyocardial growth (5) and
plasma leptin levels have been shown to be an
independent risk factor for cardiovascular disease
(6). Several recent studies have demonstrated that
leptin is principally cleared by the kidney. Thus,
serum leptin concentrations are increased in patients
with chronic renal failure and those undergoing
maintenance dialysis (7). In contrast to preliminary
studies, its role in chronic kidney disease (CKD) and
hemodialysis (HD) patients is not completely
understood. For example, though serum leptin is
generally elevated in CKD and HD patients, some
recent studies have not shown to be a cause of
uremia-related anorexia (8,9) and more recent
studies on maintenance dialysis patients have
suggest a paradoxically inverse association between
higher serum leptin and improved markers of
nutritional status (9-11), a finding that is consistent
with the theory of reverse epidemiology (9-13).
Indeed, leptin, similar to serum albumin, has been
reported to be a negative acute phase reactant in the
end-stage renal failure patients (7). Studies
concerning the influence of serum leptin
concentration in maintenance hemodialysis patients
(MHPs) is scarce, too. In a recent study, no
significant relation between leptin and LV mass (18)
have been found. This study was designed to
investigate the potential relationship between left
ventricular hypertrophy and fraction with serum
leptin in the end-stage renal failure patients under
going regular hemodialysis treatment.
PATIENTS AND METHODS
Protocol
Patients
The protocol conformed to the ethical
guidelines of our university, and a consent was
obtained from each patient. All studies were
performed on non-dialysis days, between 8 a.m. and
10 a.m.
This cross-sectional studywas carried out on
the patients with an end-stage renal disease (ESRD),
undergoing maintenance hemodialysis (HD)
treatment with acetate basis dialysate and
polysulfone membranes. There were forty-one
study patients with no clinical evidence of heart
failure (defined as dyspnoea in addition to two of the
following conditions: increased jugular pressure,
bibasilar crackles, pulmonary venous hypertension,
or interstitial edema in chest x-rays, requiring
hospitalization or extra ultrafiltration). Also, active
or chronic infection were the exclusion criteria.
These patients were assembled between January and
May, 2005 and represented approximately 90% of
the entire hemodialysis population of our dialysis
unit.
According to the severity of secondary
hyperparathyroidism, those patients were given oral
active vitamin D3 (Calcitriol; Rocaltrol) (Roche
Hexagon; Roche Laboratories Inc, New Jersey,
USA), calcium carbonate capsule, and Rena-Gel
(sevelamer; Genzyme Europe B.V.; United
Kingdom/Ireland) tablets of various doses.
According to the severity of anemia, patients
were prescribed intravenous iron therapy with Iron
Sucrose [Venofer (international) Inc. St. Gallen /
Switzerland] of various doses after each dialysis
session.
Also, all patients received treatments of 6
mg folic acid daily, 500 mg Acetyl-L-Carnitine
(Jarrow Formulas, Inc LosAngeles, CA) daily, oral
vitamin B-complex tablets daily, and 2,000 U
intravenous Eprex (recombinant human erythro
poietin [rHuEPO] (Janssen-Cilag; CILAG- AG
International 6300 Zug/Switzerland) after each
dialysis session.
All the patients received antihypertensive
drugs mainly with and ß-blockers (amlodipine,
atenolol) and a few of the patients underwent the
treatment with angiotensin-converting enzyme
inhibitors (enelapril), AT receptor antagonists
(losartan).
Blood samples were obtained after an
overnight fast. Each blood sample was centrifuged
within 15min. Serum leptin (normal range of values
for men is 3.84 ng/mL [±1.79] and for women is 7.36
ng/mL [±3.73]) was measured by enzyme-linked
immunosorbent assay (ELISA) using DRG kits
(DRG Diagnostics, Berlin, Germany). Complete
blood count containing hemoglobin (Hgb),
hematocrit (Hct) was measured using Sysmex-KX-
21N cell counter (SYSMEX CORPORATION;
Mundelein, Illinois, Sysmex America, Inc.). Also,
levels of serum predialysis creatinine and post- and
predialysis BUN, calcium (Ca), phosphorus (P),
serum albumin (Alb) and serum ferritin (by RIA
method) were measured using standard kits. The
body-mass index (BMI) was calculated using a
standard formula (post-dialyzed weight in kilo
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patients= 41
Age ( years)
DH* (months)
Dialysis
dose
(sessions)
URR ( %)
Ca ( mg/d)l
Alb (g/dL)
Hgb (g/dl)
HCT (%)
Leptin (ng/ml)
P ( mg/dl)
BMI kg/m
Ferritin (ng/dl)
LV ejection fraction (%)
2
Minimum
16
2
18
39
5
2.4
5
14
0.10
3
16
35
20
Maximum
80
156
1584
76
10
5
13
42
73
10
34
1250
65
Mean±SD
46±17.6
29.5±34
268±374
59±8.8
7.7±0.99
3.8±0.50
9±2
28±6
9.5±13.8
6±1.9
21.5±4
497±286
49±11
Median
44
18
153
58
8
4
9
29
4.7
6.4
20
420
55
Table 1: Mean ±SD, M\minimum and maximum of age,
duration and doses of hemodialysis and patients'
laboratory results
Table 2: Distribution frequency of left ventricular
hypertrophy (LVH) in hemodialysis patients
*Duration of hemodialysis treatment
Stages
LVH Mild
Modrate
Sever
Total
Frequency
13
18
10
41
Percent
31.7
43.9
24.4
100.0
Figure 1: Significant positive correlation
between LV ejection fraction and logarithm of serum
grams/height in meters to present mass per m ). For
the efficacy of hemodialysis, the urea-reduction rate
(URR) was calculated from pre- and post-blood urea
nitrogen (BUN) data (14). Duration and dosage of
hemodialysis treatment were calculated from the
patients' records.
All echocardiographic measurements were
performed according to recommendations of the
American Society of Echocardiography (15) On the
basis of septal thickness, the patients stratified into
no LVH (septal thickness from 6 to11 mm), mild
(septal thickness from11 to15mm),moderate (septal
thickness from 15 to18mm) and severe LVH (septal
thickness >18 mm) (4,16). LVH measurements were
done at the end diastolic phase and by a single
cardiologist. Percents of LV ejection fraction
between 55 and 75%were considered normal (4,16).
The data are expressed as mean ± SD,
median values and as frequency distributions. For
correlations related to the LVejection fraction partial
correlation test and for correlations related to left
ventricular hypertrophy, Kruskal-Wallis test were
used. Duration and doses of hemodialysis treatment
were calculated from patients' records and each
hemodialysis session was in duration of four hours.
To normalize the serum leptin data, evaluate its
correlation with LV ejection fraction, the logarithm
of serum leptin data was used.All statistical analysis
was performed using the SPSS package (version
11.5.00) (SPSS Inc, Chicago, IL). Statistical
significancewas determined at a value<0.05.
There was a total of 41 patients (15 women,
26 men). The main clinical and biochemical cha
racteristics of the study population are summarized
in Table 1. The mean patient' age was 46 (±17.6)
years. The mean hemodialysis duration was 29.5
(±34) months (median: 18months). Themean serum
leptin was 9.5±13.8 ng/ml (median: 4.7 ng/ml).
Table 2 summarizes the frequency distribution of
LVH stages. Mean±SD of LV ejection fraction of
patients was 49±11% (median=55%). In this study,
no significant association between stages of LVH
and serum leptinwas observed ( N.S.).Asignificant
positive correlation (r=0.32, p=0.048) between LV
ejection fraction and logarithm of serum leptin
(adjusted to age, duration and doses of dialysis, BMI,
DM, serum ferritin, calcium, phosphorus, and serum
Alb)was recorded
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DISCUSSION
Leptin has been shown to have sympathetic
and vascular effects, and may increase cardiovascu
lar risk through increased blood pressure, left ventri
cular hypertrophy, or atheroscleroticmechanisms (5,
6). Leptin is characterized by cardio-renal effects,
potentially contributing to obesity-related hyper
tension including generalized sympathoactivation
-
-
-
(5, 6). One possibility is that leptin resistance is
confined to the metabolic effects of leptin, with
preservation of its sympathoexcitatory actions.
Other mechanisms may contribute to the pressor
effects of leptin. For instance, angiotensin II induces
leptin generation. Leptin also potentiates the pressor
effect of insulin. Therefore, interactions between
angiotensin II and insulin with leptin could have
deleterious cardiovascular effects in obesity.
Additionally, leptin appears to stimulate vascular
inflammation, oxidative stress and hypertrophy.
These actions may contribute to the pathogenesis of
hypertension, atherosclerosis and left ventricular
hypertrophy (17). In the present study, a significant
positive correlation betweenLVejection fraction and
leptin was also recorded. No significant association
between stages of LVHand serum Leptinwas found.
In accordance with our finding, regarding the
association between left ventricular hypertrophy and
leptin, Zoccali et al. conducted a study on 198
patients with the end-stage renal failure. They
showed that leptin was unrelated to LV mass and to
systolic function (18). Previously, we have shown a
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protective role of leptin in hemodialysis patients
(13). Based on the recent studies, regarding the
reverse epidemiology role of Leptin in MHPs (6-8,
13) and the study of Zoccali et al (18), leptin might
not be an aggravator for LV hypertrophy. This
behavior of leptin in maintenance hemodialysis pa-
tients, which is in contrast to general population,
especially in obese patients with normal renal
function, could be explained through its reverse epi-
demiological role in hemodialysis patients.
CONCLUSION
Our results emphasize the importance of
leptin in hemodialysis and clinical impact of these
findings on further investigations.
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KONCENTRACIJA SERUMSKOG LEPTINA I HIPERTROFIJA LEVE
KOMORE I FUNKCIJA KOD PACIJENATA NA DIJALIZI
S ŽETAK
Cilj studije bio je da se ispita potencijalni odnos i u hipertrofije leve
komore i frakcije sa serumskim leptinom kod pacijenata u završnoj fazi bubrežne
insuficijencije, koji su podvrgnuti redovnom tretmanu hemodijalize. U unakrsnu
studiju bio je 41 pacijent (15 žena i 26 muškaraca) u završnoj fazi bolesti
bubrežne insuficijencije. Pacijenti su bili na dijalizi acetatnim dijalizatom i
polisulfonilnimmembranama.Vrednosti serumskog leptina i predijaliznog creatinina,
pre i postdijaliznog BUN-a, kalcijuma (Ca), fosfora (P), serumskog albumina (Alb) i
serumskog feritina su kod pacijenata gradirane u one bez hipertrofije leve komore, i u
one sa blagom, umerenom i ozbiljnom hipertrofijom k
17,6).
Srednja vrednost trajanja dijalize je 29, 5 (±34) meseci (medijana 18 meseci). Srednja
vrednost serumskog leptina je 9,5±13,8 ng/ml (medijana 4,7 ng/
nomdobu, trajanju
i dozi dijalize, BMI, DM, serumskom feritinu, kalcijumu, fosforu i serumskom
albuminu). Leptin ne mora da bude uzrok pogoršanja hipertrofije leve komore. Uloga
leptina u tretmanu pacijenata na dijalizi
se objasniti kroz njegovu inverznu epidemiološku ulogu kod pacijenata na
hemodijalizi
azanadalja istraživanja.
leptin, hemodijaliza, hipertrofija leve komore, završna faza
bubrežne insuficijencije
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A
zmeđ
uključen
leve komore, u s ladu sa
urađenim ehokardiografima. Srednje starosno doba pacijenata je 46 godina (±
ml). U studiji nije
zabeležena značajna povezanost između faza hipertrofije leve komore i serumskog
leptina. Takođe, uočena je pozitivna korelacija između ejekcione frakcije leve komore
i logaritma seruskog leptina (r= 0,32, p=0,048) (prilagođena staros
, što je u suprotnosti sa većim delom
populacije, naročito gojaznimpacijentima sanormalnombubrežnom funkcijom,može
. Naši rezultati naglašavaju značaj leptina kod hemodijalize i klinički
uticaj ovihnal
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